...
首页> 外文期刊>International Journal of Pharmaceutics >Development and comparison of intramuscularly long-acting paliperidone palmitate nanosuspensions with different particle size
【24h】

Development and comparison of intramuscularly long-acting paliperidone palmitate nanosuspensions with different particle size

机译:粒径不同的肌内长效帕潘立酮棕榈酸酯纳米混悬剂的研制与比较

获取原文
获取原文并翻译 | 示例
           

摘要

The main purpose of this study was to develop and compare the pharmacokinetic behavior of two paliperidone palmitate (PP) nanosuspensions with different particle size after intramuscular (i.m.) administration. PP nanosuspensions were prepared by wet media milling method and the mean particle size of nanosuspension was controlled as 1041 ± 6 nm (A) and 505 ± 9 nm (B), respectively. The morphology of nanosuspensions was observed by scanning electron microscope (SEM). Differential scanning calorimeter (DSC) and powder X-ray diffraction (PXRD) confirmed the crystallinity of PP in nanosuspensions. The physical and chemical stabilities of nanosuspensions A and B were investigated by particle analyzer and HPLC after storage for 2 months at 25 °C, 4°C and mechanical shaking condition. No obvious change in particle size and chemical degradation of drug were observed. Following single-dose i.m. administration to beagle dogs, the release of paliperidone lasted for nearly 1 month. The Tmax of nanosuspensions A and B was 6 (d) and 10 (d). The AUC0-t and Cmax of nanosuspensions A was 2.0-fold and 1.8-fold higher than nanosuspensions B (p 0.05). The results demonstrated that PP nanosuspensions formulation had long-acting effect. Nanosuspension A with a larger particle size performed better than nanosuspension B. As a result, it is important to design appropriate particle size of nanosuspensions for i.m. administration in order to produce larger therapeutic effect.
机译:这项研究的主要目的是在肌肉(i.m.)给药后开发和比较两种不同粒径的帕潘立酮棕榈酸酯(PP)纳米混悬剂的药代动力学行为。通过湿介质研磨法制备PP纳米悬浮液,将纳米悬浮液的平均粒径分别控制为1041±6 nm(A)和505±9 nm(B)。通过扫描电子显微镜(SEM)观察纳米悬浮液的形态。差示扫描量热仪(DSC)和粉末X射线衍射(PXRD)证实了纳米悬浮液中PP的结晶度。在25°C,4°C和机械摇动条件下储存2个月后,通过粒子分析仪和HPLC研究了纳米悬浮液A和B的物理和化学稳定性。没有观察到粒径和药物化学降解的明显变化。单次服药后在给比格犬给药后,帕潘立酮的释放持续了将近1个月。纳米悬浮液A和B的Tmax为6(d)和10(d)。纳米悬浮液A的AUC0-t和Cmax比纳米悬浮液B高2.0倍和1.8倍(p <0.05)。结果表明,PP纳米悬浮液配方具有长效作用。具有较大粒径的纳米悬浮液A的性能优于纳米悬浮液B。因此,重要的是为i.m设计合适的纳米悬浮液粒径。给药以产生更大的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号